Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Ironwood Pharmaceuticals (IRWD) over the last 14 years, with Sep 2025 value amounting to $2,000.

  • Ironwood Pharmaceuticals' Capital Expenditures fell 87.50% to $2,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $51,000, marking a year-over-year decrease of 85.55%. This contributed to the annual value of $142,000 for FY2024, which is 47.99% down from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Capital Expenditures stood at $2,000, which was down 0.00% from $2,000 recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Capital Expenditures high stood at $211,000 for Q4 2023, and its period low was -$27,000 during Q4 2022.
  • In the last 3 years, Ironwood Pharmaceuticals' Capital Expenditures had a median value of $31,000 in 2025 and averaged $50,000.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Capital Expenditures slumped by 121.09% in 2022 and then soared by 881.48% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Capital Expenditures (Quarterly) stood at $128,000 in 2021, then slumped by 121.09% to -$27,000 in 2022, then skyrocketed by 881.48% to $211,000 in 2023, then slumped by 67.35% to $16,000 in 2024, then slumped by 87.50% to $2,000 in 2025.
  • Its Capital Expenditures was $2,000 in Q3 2025, compared to $2,000 in Q2 2025 and $31,000 in Q1 2025.